Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 7, 2010

Shire’s Transdermal Patch for ADHD Gets FDA Thumbs Up for Use in Adolescents

  • FDA has cleared Shire’s Daytrana® transdermal patch for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents aged 13-17 years. The methylphenidate patch system is already cleared in the U.S. for the treatment of children aged 6-12 years.

    Daytrana is indicated for use as part of a total treatment program for ADHD that can include psychological, educational, and social measures.

    Approval of Daytrana for the new age group is based on data from a Phase IIIb trial in 217 adolescents diagnosed with ADHD. Shire said the results showed use of the patch treatment led to significant reductions in the ADHD Rating Scale-IV total score from baseline compared with treatment using placebo.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »